CD8A and neoplasm: We found that ACM‐encapsulated OVA generated higher frequencies of anti‐tumour H‐2Kb‐SIINFEKL‐specific CD8+ T cells in the blood on day 26 post prime immunisation, as compared to free OVA (~ 10% and 1.5%, respectively) (Figure 3B).